In a cohort of 57 ALL patients, the incidence of TP53 mutation, one TP53 allele deletion, and promoter hypermethylation was 8.8%, 7.5%, and 32% respectively [11]. This evidence concerns the gene TP53 and acute lymphoblastic leukemia.